Actavis has launched a generic version of Intuniv (guanfacine hydrochloride), as part of a settlement agreement with Shire plc. Actavis has begun shipping the product and, under applicable Hatch Waxman Rules, is entitled to 180 days of marketing exclusivity.
Intuniv is a prescription medicine used to treat Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 to 17. For the 12-month period ending June 30, 2014, Intuniv had US sales of approximately $668 million, according to IMS Health data.